Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).
FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
Read More
Tailoring Treatments to Better Outcomes in Liver Cancer
In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
Listen
Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.
Balancing Clinical Data and Real-World Insights in CML Treatment
In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.
FDA OKs Study of Amezalpat in Frontline Liver Cancer
The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.
Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine
Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.